Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Magdeburg – page 19

251 clinical trials in Magdeburg, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Magdeburg at a glance
251
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

251 trials in Magdeburg

Open in trial search

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluconazole
  • Sponsor:Mundipharma Research Limited

Acute lymphocytic leukaemia

Not recruiting

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Hypercholesterolaemia

Not recruiting

Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Gastrooesophageal cancer

Not recruiting

Study on Regorafenib and Nivolumab for Patients with Advanced Gastro-Oesophageal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Obesity+1

Not recruiting

Study on the Safety and Effects of AZD9550 for Overweight and Obese Patients with Non-Alcoholic Steatohepatitis (NASH) with or without Type 2 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus+2

Not recruiting

Study of LY3502970 for Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Magdeburg

What the registry says about research in the country

01 Oncology Research

Clinical investigations focusing on innovative treatments for various cancer types, including breast cancer, lymphoma, and pancreatic cancer. Studies evaluate new therapeutic approaches and combination treatments.

  • HER2-positive metastatic breast cancer therapies
  • Diffuse Large B-Cell Lymphoma treatments
  • Advanced pancreatic cancer interventions

Particular emphasis on targeted therapies and immunotherapy approaches for better patient outcomes.

02 Dermatology Studies

Research focusing on chronic skin conditions and innovative treatments for psoriasis and other dermatological disorders. Multiple trials investigating new therapeutic options.

  • Moderate to severe plaque psoriasis
  • Prurigo nodularis treatments
  • Lichen simplex chronicus management

Studies aim to improve quality of life through advanced therapeutic approaches.

03 Cardiovascular and Metabolic Research

Investigations into treatments for cardiovascular disease and metabolic disorders, including innovative approaches for managing hypertriglyceridemia and diabetes.

  • Cardiovascular risk reduction
  • Type 2 diabetes management
  • Lipid disorder treatments

Focus on preventive strategies and novel therapeutic interventions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.